Everything below concerns CJC-1295. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
=== Drugs === Drugs can have various types of impact on the male body, side effects of medications may affect male fertility, spermatogenesis, and sexual function. Drugs can affect sperm parameters by inhibiting normal exocrine functions of the testes which can lead to a decrease in production of sperm, or by creating hormone imbalances. For an example, anti-androgenic drugs like spironolactone, cimetidine, and ketoconazole can disrupt androgens in the glands and seminal tract to cause a decrease in production of semen volume. Furthermore, common drugs (e.g. tamsulosin) used to treat hypertension and benign prostatic hyperplasia (increased size of prostate) are attracted to dopamine and serotonin receptors in the brain to cause a decrease in sperm volume through a mechanism that remains unknown. Certain medications in the following classes of drugs may affect spermatogenesis or sperm parameters*:
=== Infection === Stomach acid plays a role in killing ingested bacteria. Use of pantoprazole may increase the chance of developing infections such as pneumonia, particularly in hospitalized patients.
On 25 February 2026, the United States Department of the Treasury imposed sanctions on more than 30 individuals, entities, and vessels linked to Iran's oil shipping network and other designated activities. On 28 February 2026, Israel and the United States launched airstrikes against Iran, killing its supreme leader and many other officials, destroying a large number of military and government targets, and killing civilians. Iran responded with missile and drone strikes against Israel, US bases, and US-allied countries in the Middle East, and by closing the Strait of Hormuz, disrupting global trade. US president Donald Trump wrote on 6 March 2026 that "There will be no deal with Iran except UNCONDITIONAL SURRENDER!". On 9 March, Trump said that "the war is very complete, pretty much", and falsely claimed that the Iranian military had been destroyed and the Strait of Hormuz had re-opened. On 15 March he demanded that NATO and China help the US to re-open the strait. Trump again claimed on 24 March that the US and Israel had "won" the war, even though Iran continued its missile strikes. In late March, Trump repeatedly threatened to destroy Iran's infrastructure if it did not make a "deal" with the US and re-open the Hormuz strait. Trump said on 23 March that the US has been speaking to "a top person" in Iran and claimed "They called, I didn't call. They want to make a deal, and we are very willing to make a deal". The IRGC-affiliated Fars News denied there had been any negotiations with Trump.
Blood is circulated around the body through blood vessels by the pumping action of the heart. In humans, blood is pumped from the strong left ventricle of the heart through arteries to peripheral tissues and returns to the right atrium of the heart through veins. It then enters the right ventricle and is pumped through the pulmonary artery to the lungs and returns to the left atrium through the pulmonary veins. Blood then enters the left ventricle to be circulated again. Arterial blood carries oxygen from inhaled air to all of the cells of the body, and venous blood carries carbon dioxide, a waste product of metabolism by cells, to the lungs to be exhaled. However, one exception includes pulmonary arteries, which contain the most deoxygenated blood in the body, while the pulmonary veins contain oxygenated blood. Additional return flow may be generated by the movement of skeletal muscles, which can compress veins and push blood through the valves in veins toward the right atrium. The blood circulation was described by William Harvey in 1628.
The IQOS is a heated tobacco product marketed by Philip Morris International. It heats tobacco at a lower temperature than traditional cigarettes. The tobacco sticks reach a temperature up to 350 °C. It sold first in Japan since November 2014. In December 2016, the United Tobacco Vapor Group's (UTVG) stated that they have been given a patent for their vaporizing component system. QMOS from UTVG does not contain a wick or sponge and the number of components is 5 compared to 20 for traditional e-cigarettes. Pax Labs has developed vaporizers that heats the leaves of tobacco to deliver nicotine in a vapor. In June 2015, they introduced Juul, a type of e-cigarette which delivers 10 times as much nicotine as other e-cigarettes, equivalent to an actual cigarette puff. Juul was spun off from Pax Labs in June 2017 and is now available by the independent company Juul Labs. The eTron 3T from Vapor Tobacco Manufacturing, launched in December 2014, employs a patented, aqueous system whereby the tobacco is extracted into water. The e-liquid contains organic tobacco, organic glycerin, and water. In December 2013, Japan Tobacco launched Ploom in Japan. In January 2016, they launched Ploom TECH that produces a vapor from a heated liquid that moves through a capsule of granulated tobacco leaves. In 2016, British American Tobacco (BAT) released its own version of the heat but not burn technology called glo in Japan and Switzerland. It uses tobacco sticks rather than nicotine liquid, and does not directly heat or burn tobacco.
Sources: en.wikipedia.org
== Consumption by region == Penis is a taboo food in many cultures, even those that consume copious offal; anthropologist Robert Rotenberg opines that the symbolic association of penis to coitus, urination and ejaculation makes consuming it off-putting. Even in areas where penis is consumed, it is typically a niche food and eaten under specific circumstances, such as when their purported health benefits are needed.
=== Christmas Island Phosphate Company === The first European to recommend mining of phosphate for commercial exploitation was Sir John Murray, a British naturalist, during the 1872–76 Challenger expedition. His discovery led to annexation of the island by the British Crown on 6 June 1888. In 1900 the Pacific Islands Company Ltd commenced mining on Ocean Island, with 1550 tons shipped from September to December 1901 and 13,350 tons in the following year. John T. Arundel and Lord Stanmore, directors of PIC, were responsible for financing the new opportunities and negotiating with the German company that controlled the licences to mine in Nauru. In 1902 the interests of PIC were merged with Jaluit Gesellschaft of Hamburg, to form the Pacific Phosphate Company Ltd (PPC), to engage in phosphate mining in Nauru and Ocean Island.
=== Pharmacokinetics === When administered orally, CBN demonstrates a similar metabolism to Δ9-THC, with the primary intoxicating metabolite being produced through a hydroxylation reaction that occurs in the liver. The active metabolite generated via this process is called 11-OH-CBN, which is around two times as potent as CBN, and has demonstrated activity as a weak CB2 antagonist. This metabolism starkly contrasts that of standard cannabis edibles in terms of potency, given that 11-OH-THC has been reported to have 10× the potency of Δ9-THC. Due to high lipophilicity and first-pass metabolism, there is low bioavailability of CBN and other cannabinoids following oral administration. CBN metabolism is mediated in part by CYP450 isoforms 2C9 and 3A4. The metabolism of CBN may be catalyzed by UGTs (UDP-glucuronosyltransferases), with a subset of UGT isoforms (1A7, 1A8, 1A9, 1A10, 2B7) identified as potential substrates associated with CBN glucuronidation. The bioavailability of CBN following administration via inhalation (e.g., smoking or vaporizing) is approximately 40% that of intravenous administration. A small study of six cannabis users found a highly variable half life of 32 ± 17 hours upon intravenous administration. Similar to CBD, CBN is metabolized by the CYP2C9 and CYP3A4 liver enzymes and thus the half-life is sensitive to genetic factors that effect the levels of these enzymes.
is a certain constant called the "calorimetric constant". That particular constant varies from instrument to instrument, and can be measured by performing DSC on a calibration sample whose enthalpies of transition is known accurately. This curve can also be used to calculate the molar specific heat capacity as a function of temperature. To obtain this, one perform DSC with two samples. One sample is a reference sample whose molar specific heat capacity
To overcome this effect, a new index was created, named the Equatorial Southern Oscillation Index (EQSOI). To generate this index, two new regions, centered on the Equator, were defined. The western region is located over Indonesia and the eastern one over the equatorial Pacific, close to the South American coast. However, data on EQSOI goes back only to 1949. Sea surface height (SSH) changes up or down by several centimeters in Pacific equatorial region with the ENSO: El Niño causes a positive SSH anomaly (raised sea level) because of thermal expansion while La Niña causes a negative SSH anomaly (lowered sea level) via contraction.
Sources: en.wikipedia.org
Immobilized metal ion affinity chromatography (IMAC) is based on the specific coordinate covalent bond of amino acids, particularly histidine, to metals. This technique works by allowing proteins with an affinity for metal ions to be retained in a column containing immobilized metal ions, such as cobalt, nickel, or copper for the purification of histidine-containing proteins or peptides, iron, zinc or gallium for the purification of phosphorylated proteins or peptides. Many naturally occurring proteins do not have an affinity for metal ions, therefore recombinant DNA technology can be used to introduce such a protein tag into the relevant gene. Methods used to elute the protein of interest include changing the pH, or adding a competitive molecule, such as imidazole.
Two different kinds of blank may be measured: a sample of dead carbon that has undergone no chemical processing, to detect any machine background, and a sample known as a process blank made from dead carbon that is processed into target material in exactly the same way as the sample which is being dated. Any 14C signal from the machine background blank is likely to be caused either by beams of ions that have not followed the expected path inside the detector or by carbon hydrides such as 12CH2 or 13CH. A 14C signal from the process blank measures the amount of contamination introduced during the preparation of the sample. These measurements are used in the subsequent calculation of the age of the sample.
1996: Insulin lispro, which was originally manufactured by Eli Lilly and Company, is granted approval. 2000: Insulin aspart, which was created by Novo Nordisk, is approved. 2000: Insulin glargine, which was developed by Sanofi-Aventis, is approved. 2004: Insulin glulisine, also developed by Sanofi-Aventis, is approved. 2005: Insulin detemir, which was formulated by Novo Nordisk, gets approval. 2015: Insulin degludec, created by Novo Nordisk, is approved. 2020: Insulin lispro-aabc, a faster insulin lispro formulation created by Eli Lilly and Company, is approved. 2021: Insulin glargine-yfgn, the first approved insulin biosimilar, which is produced by Viatris, is approved. 2021: Insulin glargine-aglr, a biosimilar produced by Eli Lilly and Company, is granted approval. 2024: Insulin icodec, the newest commercially available analogue by Novo Nordisk, gets approval. 2025: Insulin aspart-szjj, the first short-acting biosimilar, created by Viatris, is approved.
Independent scholar Mikhail Berg compared the war in Georgia to the German occupation of Czechoslovakia where the Sudeten Germans refused any offers of autonomy and instead were provoking the Czechoslovak authorities until the latter was forced to use force and then Germany intervened. Historian Boris Vadimovich Sokolov also made a similar comparison of the Russian attack on Georgia with the German annexation of Sudetenland. In August 2008, Aleksandr Golts, a Moscow-based defense analyst stated, "Russia's policies over the past several years caused this war. And for this they bear responsibility." In August 2008, Yulia Latynina, Russian journalist, observed when the Georgians took the Sarabuk height, from which the military movement from Ossetian-controlled Java to Ossetian-controlled Dmenisi could be observed, the exchanges became frequent. By that time, Java had been turned into a military base, located beyond the demilitarised zone, where any amount of artillery and armored vehicles could be deployed. Latynina suggested that the main aim of the Georgian army was not Tskhinvali, but Java and to block the Transcaucasian Highway above Java since the Roki Tunnel could not be blown up. If Java had been taken by the Georgians, then Saakashvili would have exposed the arsenal stored there to the world, which Russia could not allow. In August 2008, Georgy Satarov, head of the InDem Foundation, said: "President Medvedev sent troops to the Georgian-Ossetian conflict zone without approval of the Federation Council.
Capillary blood draws are generally used for infants and individuals whose veins are difficult to access. To prevent clotting, the sample is drawn into a tube containing the anticoagulant compound ethylenediaminetetraacetic acid (EDTA), meaning blood that has not been centrifuged.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.